SecBot SecBot
Biotech Drug Report Generated Oct 29, 2026

INCA33890

INCY·INCYTE CORP
NEUTRAL
Drug Impact Rating4/10
Trial phase
Phase 3
Time to market
Likely 2029 or later. The Phase 3 NEXERA-303 primary completion is estimated at December 2028, with topline data expected in 2029. If positive, an NDA filing would follow, putting potential approval no earlier than 2030.
Why 4/10
The next significant binary catalyst for INCA33890 is the Phase 3 NEXERA-303 topline readout, which is not expected until 2029, more than 12 months away. With no dated near-term binary catalyst, the impact score defaults low. Furthermore, INCA33890 is one of several pipeline assets at Incyte, a diversified biotech with approved revenue drivers (Jakafi, etc.), so this single drug does not comprise most of the company's value.
Actionable Insight NEUTRAL

The next hard catalyst is the Phase 3 NEXERA-303 topline readout, but that is not expected until 2029, more than 12 months away. Investors should watch for interim Phase 1/2 combination updates (including the new muzastotug combo trial) and any biomarker data that could refine the Phase 3 probability of success. Incyte's Q3 2026 earnings were reported today (Oct 29, 2026); pipeline updates in the earnings call may provide additional color on NEXERA-303 enrollment.

Price Chart

Loading chart...

Executive Summary

INCA33890 is Incyte's investigational PD-1/TGFβR2 bispecific antibody designed to overcome immunotherapy resistance in MSS colorectal cancer (a large market where checkpoint inhibitors generally fail). Phase 1 data at ESMO 2025 showed a 12% partial-response rate as monotherapy in MSS CRC. Updated ESMO 2026 data showed a 71.4% objective response rate when combined with FOLFOX/bevacizumab in first-line MSS CRC, supporting the ongoing Phase 3 NEXERA-303 trial. The Phase 3 study is enrolling at ~280 sites with topline data not expected until 2029, making this a mid-to-long-term pipeline story rather than a near-term binary catalyst for INCY shares.

How It Works

INCA33890 is a bispecific antibody, a single engineered protein that simultaneously blocks two targets: PD-1 (an immune checkpoint that tumors use to shut down T-cells) and TGFβ receptor 2 (a signaling pathway that suppresses immune responses in the tumor environment). By targeting both only on cells that co-express them, the drug aims to restore the immune system's ability to attack tumors, particularly in types of colorectal cancer that do not respond to standard PD-1/L1 inhibitors alone.

Trial Status

Phase 1 monotherapy and combination dose-escalation/expansion completed, presented at ESMO 2025 and ESMO 2026. The Phase 3 NEXERA-303 trial (NCT07284849) is actively recruiting at approximately 280 sites for first-line metastatic MSS colorectal cancer, with 700 patients targeted. A Phase 2 adjuvant trial (NEXERA-204, NCT07823322) is also underway for ctDNA-positive stage II/III MSS CRC after curative resection. A separate Phase 1 combination trial with Adagene's muzastotug (anti-CTLA-4) dosed its first patient on October 28, 2026.

The Two-Sided Case

▲ Bull Case4
MSS colorectal cancer represents a major unmet need (over 150,000 new US cases/year) with essentially no effective immunotherapies -- a successful INCA33890 could address a multi-billion-dollar market.
Phase 1 combination data (71.4% ORR with FOLFOX/bevacizumab in first-line MSS CRC) are compelling for an immunotherapy in a checkpoint-refractory indication, supporting the Phase 3 hypothesis.
The drug's differentiated mechanism (targeting PD-1 rather than PD-L1, and TGFβR2 only on co-expressing cells) may avoid the toxicity issues that plagued earlier TGFβ/PD-L1 bifunctional agents like bintrafusp alfa.
Adagene recently initiated a Phase 1 combo trial with muzastotug, expanding INCA33890's potential combination optionality.
▼ Bear Case4
Topline Phase 3 data are not expected until 2029, so INCA33890 provides no near-term catalyst for INCY shares and the stock will be driven by approved products and other pipeline assets.
The TGFβ/PD-(L)1 dual-targeting space has been littered with failures, including Merck KGaA/Pfizer's bintrafusp alfa which failed multiple Phase 3 trials due to toxicity and lack of efficacy.
Phase 1 monotherapy activity in MSS CRC was modest (12% ORR), raising questions about whether the combination benefit observed is driven by chemotherapy rather than INCA33890.
Insider selling by Incyte's President of R&D (Pablo Cagnoni) and other executives in recent months, along with elevated short-sale volume, suggest mixed sentiment around the stock.

Upcoming Catalysts

  • Phase 1 combination data updates for INCA33890 + muzastotug (anti-CTLA-4) in MSS CRC (ongoing)
  • Further biomarker and expansion cohort data from the Phase 1 program
  • NEXERA-303 (Phase 3) enrollment updates
  • NEXERA-204 (Phase 2 adjuvant) data in ctDNA-positive stage II/III MSS CRC

Source Filing

The SecBot filing or press-release report that triggered this drug report:

INCYTE CORP 8-K INCY ·Originating report

Sources · 12

Hover a chip for the title
1 investor.incyte.com2 investor.incyte.com3 investor.incyte.com4 marketscreener.com5 trial.medpath.com6 clinicaltrials.gov7 cancer.gov8 markets.businessinsider.com9 spzco.com10 biospace.com11 sec.gov12 ascopubs.org